EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
- Study type
- Clinical guideline
- Study name
- EHA-EMN Multiple Myeloma Guidelines 2025
- Design
- Evidence-based clinical guideline developed by a multidisciplinary group of experts from the European Hematology Association (EHA) and the European Myeloma Network (EMN)
- Source
- Nat Rev Clin Oncol · 2025
In plain words
This article is an updated European guideline that helps doctors diagnose and treat multiple myeloma and follow patients up. In recent years, new ways of assessing prognosis and new treatments for this disease have been approved, and this guideline takes them into account. The guideline also covers managing problems such as bone involvement, kidney problems and infections. The right treatment should always be chosen with your treating doctor.
Study population
The guideline was developed for patients with multiple myeloma (MM) and smouldering multiple myeloma (SMM), including newly diagnosed patients and patients with relapsed and/or refractory disease.
Endpoints
This article is a guideline and has no trial endpoints. The abstract reports algorithms for everyday clinical use that include levels of evidence and grades of recommendation based on new data.
Safety and side effects
The abstract does not report rates of grade 3 or higher adverse events. The guideline includes recommendations for managing myeloma-related complications and adverse events (such as bone disease, renal failure and infections) as well as adverse events related to T-cell-engaging therapies (such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome). Details are in the full text of the paper.
Clinical significance and place in guidelines
This guideline updates the 2021 EHA guideline for multiple myeloma and, based on new data, including the R2-ISS staging system, novel prognostic factors (minimal residual disease, circulating plasma cells and mass spectrometry assessment of the monoclonal protein) and 14 regimens newly approved by the EMA and/or FDA, provides algorithms for everyday practice. These algorithms cover newly diagnosed patients, relapsed/refractory patients and patients with SMM, and include the management of complications and of adverse events of T-cell-engaging therapies. The abstract does not state individual recommendations or their levels of evidence; consult the full text of the paper for each recommendation. Consistency with national or other guidelines should be checked separately.
Limitations
This card is based on the abstract of the paper; the detailed recommendations, levels of evidence and grades of recommendation are not given in the abstract. The validity of the recommendations depends on the data available at the time of writing and may need updating as new regimens are approved. Most members of the author group are from European institutions.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.